Scottsdale, AZ -- ( SBWIRE ) -- 01/25/2013 -- Universal pennystocks.com focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.

Berkshire Hathaway Inc. (NYSE:BRK-B) ended higher by 0.83 points or 0.86% to complete the day at 97.31. The total number of shares changed hands during the day was 4.84 million. After opening at $96.59, the stock hit as high as $97.73. However, it traded between $77.89 and$97.73 over the last twelve months. Berkshire Hathaway, Inc. is a publicly owned investment manager. Through its subsidiaries, the firm primarily engages in the insurance and reinsurance of property and casualty risks business. Berkshire Hathaway was founded in 1889 and is based in Omaha, Nebraska.

What was the Moving Force behind BRK-B On Bullish Run? Read This Research Report on BRK-B

Keryx Biopharmaceuticals (NASDAQ:KERX) closed yesterday at $3.59, a -6.02% decrease. Around 4.49 million shares were traded, beating an-average trading volume of 1.64 million shares. The company is now valued at around $258.21 million. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.

Will KERX Get Buyers Even After The Recent Rally? Find Out Here

Peregrine Pharmaceuticals (NASDAQ PHM) moved -2.36 per cent lower at $2.07 and traded between $2.02 and $2.14 after opening the day at $2.14. Its performance over the last five days remained -1.43%, which stands at 72.5% for a month. Going back further than one month, 1-year performance after recent close was 122.58%. Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment and diagnosis of cancer and viral infections.

Why Should Investors Buy PPHM After the Recent Fall? Just Go Here and Find Out

North American Palladium Ltd (USA) (NYSE AL) shares decline, decreasing -6.32 per cent to close at $1.63. The stock is up around 25.38% this year and -30.34% for the last 12 months. Around 3.29 million shares changed hands yesterday, higher from an-average trading volume of 2.63 million shares. North American Palladium Ltd. engages in the exploration, mining, and production of precious metal properties in Canada.

Has PAL Found The Bottom And Ready To Gain Momentum? Find Out Here

The share price of Amicus Therapeutics, Inc. (NASDAQ:FOLD) after ranging between $3.50 and $3.70 ended -0.27% lower to settle at $3.66.During the past 52 weeks, the stock has ranged from a high of $7.29 to a low of $2.47.So far this year, shares have gained 36.57% and 1-year performance was around -41.25%. Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of lysosomal storage disorders and diseases of neurodegeneration.

Has FOLD Found The Bottom and Ready To Move Up? Find Out Here

About Universal Penny Stocks
Universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “ penny stocks ”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.

We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.